Report Thumbnail
Product Code LP0913415486EHI
Published Date 2024/7/9
English83 PagesGlobal

Global Management of Acromegaly Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0913415486EHI◆The Jul 2025 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/7/9
English 83 PagesGlobal

Global Management of Acromegaly Market Growth (Status and Outlook) 2024-2030Pharmaceutical_LifeSciense Market



Abstract


Summary

Acromegaly is a rare endocrine disorder characterized by excessive production of growth hormone, which may lead to abnormal growth of the bones and soft tissues, including the face, hands, and feet. The management of acromegaly includes both medical and surgical options.
The global Management of Acromegaly market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “Management of Acromegaly Industry Forecast” looks at past sales and reviews total world Management of Acromegaly sales in 2022, providing a comprehensive analysis by region and market sector of projected Management of Acromegaly sales for 2023 through 2029. With Management of Acromegaly sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Management of Acromegaly industry.
This Insight Report provides a comprehensive analysis of the global Management of Acromegaly landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Management of Acromegaly portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Management of Acromegaly market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Management of Acromegaly and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Management of Acromegaly.
United States market for Management of Acromegaly is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Management of Acromegaly is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Management of Acromegaly is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Management of Acromegaly players cover Pfizer Inc., Chiasma Inc, Novartis AG, Ipsen Biopharmaceuticals Inc, Wockhardt Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Management of Acromegaly market by product type, application, key players and key regions and countries.
Segmentation by Type:
Ectopic Acromegaly
Pseudo Acromegaly
Segmentation by Application:
Surgery
Drug Therapy
Radiation Therapy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Ectopic Acromegaly
Pseudo Acromegaly
Segmentation by Application:
Surgery
Drug Therapy
Radiation Therapy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer Inc.
Chiasma Inc
Novartis AG
Ipsen Biopharmaceuticals Inc
Wockhardt Ltd.
Troikaa Pharmaceuticals Limited
VHB Life Sciences Limited
GlaxoSmithKline plc

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Management of Acromegaly Market Size 2019-2030
      • 2.1.2 Management of Acromegaly Market Size CAGR by Region (2019 VS 2023 VS 2030)
      • 2.1.3 World Current & Future Analysis for Management of Acromegaly by Country/Region, 2019, 2023 & 2030
    • 2.2 Management of Acromegaly Segment by Type
      • 2.2.1 Ectopic Acromegaly
      • 2.2.2 Pseudo Acromegaly
    • 2.3 Management of Acromegaly Market Size by Type
      • 2.3.1 Management of Acromegaly Market Size CAGR by Type (2019 VS 2023 VS 2030)
      • 2.3.2 Global Management of Acromegaly Market Size Market Share by Type (2019-2024)
    • 2.4 Management of Acromegaly Segment by Application
      • 2.4.1 Surgery
      • 2.4.2 Drug Therapy
      • 2.4.3 Radiation Therapy
    • 2.5 Management of Acromegaly Market Size by Application
      • 2.5.1 Management of Acromegaly Market Size CAGR by Application (2019 VS 2023 VS 2030)
      • 2.5.2 Global Management of Acromegaly Market Size Market Share by Application (2019-2024)
  • 3 Management of Acromegaly Market Size by Player

    • 3.1 Management of Acromegaly Market Size Market Share by Player
      • 3.1.1 Global Management of Acromegaly Revenue by Player (2019-2024)
      • 3.1.2 Global Management of Acromegaly Revenue Market Share by Player (2019-2024)
    • 3.2 Global Management of Acromegaly Key Players Head office and Products Offered
    • 3.3 Market Concentration Rate Analysis
      • 3.3.1 Competition Landscape Analysis
      • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
    • 3.4 New Products and Potential Entrants
    • 3.5 Mergers & Acquisitions, Expansion
  • 4 Management of Acromegaly by Region

    • 4.1 Management of Acromegaly Market Size by Region (2019-2024)
    • 4.2 Global Management of Acromegaly Annual Revenue by Country/Region (2019-2024)
    • 4.3 Americas Management of Acromegaly Market Size Growth (2019-2024)
    • 4.4 APAC Management of Acromegaly Market Size Growth (2019-2024)
    • 4.5 Europe Management of Acromegaly Market Size Growth (2019-2024)
    • 4.6 Middle East & Africa Management of Acromegaly Market Size Growth (2019-2024)
  • 5 Americas

    • 5.1 Americas Management of Acromegaly Market Size by Country (2019-2024)
    • 5.2 Americas Management of Acromegaly Market Size by Type (2019-2024)
    • 5.3 Americas Management of Acromegaly Market Size by Application (2019-2024)
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Management of Acromegaly Market Size by Region (2019-2024)
    • 6.2 APAC Management of Acromegaly Market Size by Type (2019-2024)
    • 6.3 APAC Management of Acromegaly Market Size by Application (2019-2024)
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
  • 7 Europe

    • 7.1 Europe Management of Acromegaly Market Size by Country (2019-2024)
    • 7.2 Europe Management of Acromegaly Market Size by Type (2019-2024)
    • 7.3 Europe Management of Acromegaly Market Size by Application (2019-2024)
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Management of Acromegaly by Region (2019-2024)
    • 8.2 Middle East & Africa Management of Acromegaly Market Size by Type (2019-2024)
    • 8.3 Middle East & Africa Management of Acromegaly Market Size by Application (2019-2024)
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Global Management of Acromegaly Market Forecast

    • 10.1 Global Management of Acromegaly Forecast by Region (2025-2030)
      • 10.1.1 Global Management of Acromegaly Forecast by Region (2025-2030)
      • 10.1.2 Americas Management of Acromegaly Forecast
      • 10.1.3 APAC Management of Acromegaly Forecast
      • 10.1.4 Europe Management of Acromegaly Forecast
      • 10.1.5 Middle East & Africa Management of Acromegaly Forecast
    • 10.2 Americas Management of Acromegaly Forecast by Country (2025-2030)
      • 10.2.1 United States Market Management of Acromegaly Forecast
      • 10.2.2 Canada Market Management of Acromegaly Forecast
      • 10.2.3 Mexico Market Management of Acromegaly Forecast
      • 10.2.4 Brazil Market Management of Acromegaly Forecast
    • 10.3 APAC Management of Acromegaly Forecast by Region (2025-2030)
      • 10.3.1 China Management of Acromegaly Market Forecast
      • 10.3.2 Japan Market Management of Acromegaly Forecast
      • 10.3.3 Korea Market Management of Acromegaly Forecast
      • 10.3.4 Southeast Asia Market Management of Acromegaly Forecast
      • 10.3.5 India Market Management of Acromegaly Forecast
      • 10.3.6 Australia Market Management of Acromegaly Forecast
    • 10.4 Europe Management of Acromegaly Forecast by Country (2025-2030)
      • 10.4.1 Germany Market Management of Acromegaly Forecast
      • 10.4.2 France Market Management of Acromegaly Forecast
      • 10.4.3 UK Market Management of Acromegaly Forecast
      • 10.4.4 Italy Market Management of Acromegaly Forecast
      • 10.4.5 Russia Market Management of Acromegaly Forecast
    • 10.5 Middle East & Africa Management of Acromegaly Forecast by Region (2025-2030)
      • 10.5.1 Egypt Market Management of Acromegaly Forecast
      • 10.5.2 South Africa Market Management of Acromegaly Forecast
      • 10.5.3 Israel Market Management of Acromegaly Forecast
      • 10.5.4 Turkey Market Management of Acromegaly Forecast
    • 10.6 Global Management of Acromegaly Forecast by Type (2025-2030)
    • 10.7 Global Management of Acromegaly Forecast by Application (2025-2030)
      • 10.7.1 GCC Countries Market Management of Acromegaly Forecast
  • 11 Key Players Analysis

    • 11.1 Pfizer Inc.
      • 11.1.1 Pfizer Inc. Company Information
      • 11.1.2 Pfizer Inc. Management of Acromegaly Product Offered
      • 11.1.3 Pfizer Inc. Management of Acromegaly Revenue, Gross Margin and Market Share (2019-2024)
      • 11.1.4 Pfizer Inc. Main Business Overview
      • 11.1.5 Pfizer Inc. Latest Developments
    • 11.2 Chiasma Inc
      • 11.2.1 Chiasma Inc Company Information
      • 11.2.2 Chiasma Inc Management of Acromegaly Product Offered
      • 11.2.3 Chiasma Inc Management of Acromegaly Revenue, Gross Margin and Market Share (2019-2024)
      • 11.2.4 Chiasma Inc Main Business Overview
      • 11.2.5 Chiasma Inc Latest Developments
    • 11.3 Novartis AG
      • 11.3.1 Novartis AG Company Information
      • 11.3.2 Novartis AG Management of Acromegaly Product Offered
      • 11.3.3 Novartis AG Management of Acromegaly Revenue, Gross Margin and Market Share (2019-2024)
      • 11.3.4 Novartis AG Main Business Overview
      • 11.3.5 Novartis AG Latest Developments
    • 11.4 Ipsen Biopharmaceuticals Inc
      • 11.4.1 Ipsen Biopharmaceuticals Inc Company Information
      • 11.4.2 Ipsen Biopharmaceuticals Inc Management of Acromegaly Product Offered
      • 11.4.3 Ipsen Biopharmaceuticals Inc Management of Acromegaly Revenue, Gross Margin and Market Share (2019-2024)
      • 11.4.4 Ipsen Biopharmaceuticals Inc Main Business Overview
      • 11.4.5 Ipsen Biopharmaceuticals Inc Latest Developments
    • 11.5 Wockhardt Ltd.
      • 11.5.1 Wockhardt Ltd. Company Information
      • 11.5.2 Wockhardt Ltd. Management of Acromegaly Product Offered
      • 11.5.3 Wockhardt Ltd. Management of Acromegaly Revenue, Gross Margin and Market Share (2019-2024)
      • 11.5.4 Wockhardt Ltd. Main Business Overview
      • 11.5.5 Wockhardt Ltd. Latest Developments
    • 11.6 Troikaa Pharmaceuticals Limited
      • 11.6.1 Troikaa Pharmaceuticals Limited Company Information
      • 11.6.2 Troikaa Pharmaceuticals Limited Management of Acromegaly Product Offered
      • 11.6.3 Troikaa Pharmaceuticals Limited Management of Acromegaly Revenue, Gross Margin and Market Share (2019-2024)
      • 11.6.4 Troikaa Pharmaceuticals Limited Main Business Overview
      • 11.6.5 Troikaa Pharmaceuticals Limited Latest Developments
    • 11.7 VHB Life Sciences Limited
      • 11.7.1 VHB Life Sciences Limited Company Information
      • 11.7.2 VHB Life Sciences Limited Management of Acromegaly Product Offered
      • 11.7.3 VHB Life Sciences Limited Management of Acromegaly Revenue, Gross Margin and Market Share (2019-2024)
      • 11.7.4 VHB Life Sciences Limited Main Business Overview
      • 11.7.5 VHB Life Sciences Limited Latest Developments
    • 11.8 GlaxoSmithKline plc
      • 11.8.1 GlaxoSmithKline plc Company Information
      • 11.8.2 GlaxoSmithKline plc Management of Acromegaly Product Offered
      • 11.8.3 GlaxoSmithKline plc Management of Acromegaly Revenue, Gross Margin and Market Share (2019-2024)
      • 11.8.4 GlaxoSmithKline plc Main Business Overview
      • 11.8.5 GlaxoSmithKline plc Latest Developments
  • 12 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.